Nymox
Pharmaceutical Corporation NYMX reported positive results from a
new study of long-term treatment outcomes for men who had received a single
injection of NX-1207 2.5 mg for treatment for their benign prostatic
hyperplasia (BPH). The study analysis found that a statistically significant
greater number of men who had received NX-1207 2.5 mg reported positive
treatment outcomes as compared to men who had received a placebo.
The study
involved the latest available blinded follow-up study data (an average of 57
months post-injection) from the completed clinical trials for these
treatment groups. A positive treatment outcome was seen if the patient was
not using other BPH medications and no surgical treatment (including MIST)
for BPH was reported at any time during the post-injection follow-up period.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in